Clinical Trials Logo

Endometrial Neoplasms clinical trials

View clinical trials related to Endometrial Neoplasms.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06394258 Completed - Endometrial Cancer Clinical Trials

POSE - POs Surgery Endometrial Cancer

POSE
Start date: June 18, 2018
Phase: N/A
Study type: Interventional

This phase I/II feasibility study of hypo-fractionated, image-guided Volumetric Modulated Arc Therapy (VMAT) Stereotactic Body Radiotherapy (SBRT) to the vaginal cuff in intermedium and high risk endometrial cancer. The primary endpoints are SBRT feasibility and dosimetrical reproducibility to HDR brachytherapy, inter/intra-fractional target motion assessment and toxicity rates. Secondary endpoints are quality of life measures, local control, disease free survival and overall survival.

NCT ID: NCT06312917 Completed - Physical Activity Clinical Trials

Effect of Physical Activity Intervention on Overweight and Obese Patients With Endometrial Cancer

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

This study evaluated the clinical outcome of exercise management on patients with endometrial cancer treated with fertility preservation, including the effect of complete response rate, complete response time, recurrence rate, recurrence time, etc., and physical composition, to evaluate the effectiveness of physical activity on weight management.

NCT ID: NCT06187558 Completed - Endometriosis Clinical Trials

Suspension of the Pelvic and Abdominal Organs During Minimally Invasive Surgery

Start date: March 1, 2019
Phase:
Study type: Observational

The goal of this retrospective observational study is to evaluate the efficacy, safety, and practicality of an organ suspension technique with adjustable tension suture in facilitating minimally invasive gynecologic surgeries at the University Hospital of Cagliari, Italy. The main questions it aims to answer are: - Is the organ suspension technique using adjustable tension suture both cost-effective and practical for minimally invasive gynecologic surgeries? - How safe, effective, and feasible is this suspension technique when applied to patients with benign or malignant gynecological diseases undergoing laparoscopic surgery? Participants in this study underwent laparoscopic surgery involving the organ suspension technique, which includes: - The use of a modified Foley catheter and Polyglactin suture for organ suspension. - The collection of preoperative and postoperative data, such as operation times, blood loss, hospital stay duration, and short-term postoperative complications. This study does not include a comparison group, focusing instead on the direct outcomes and experiences of the participants who underwent the specified surgical technique.

NCT ID: NCT06148129 Completed - Endometrial Cancer Clinical Trials

Immunohistochemistry Role in Better Prognosis of Endometrial Carcinoma Patients

Start date: January 12, 2019
Phase: N/A
Study type: Interventional

The incidence of endometrial cancer (EC) is increasing .Different risk classifications are used to direct the primary and adjuvant therapy. The European Society for Medical Oncology - European Society of Gynaecological Oncology -European Society for Radiotherapy & Oncology (ESMO-ESGO- ESTRO) could guide the need for lymph node surgery pre-operatively, and also post-operatively to determine adjuvant treatment. Low-risk patients are managed with surgery alone, while higher-risk group patients undergo more aggressive surgical options. So, it is important to identify new prognostic markers for better stratification of patients to avoid under- or over treatment of EC patients.

NCT ID: NCT06115577 Completed - Endometrial Cancer Clinical Trials

Endometrial Tissues and Mononuclear Cells Receptivity in Pathogenesis of Endometrial Proliferative Processes

Start date: October 1, 2012
Phase:
Study type: Observational

A prospective observational study of endometrial tissue and peripheral blood mononuclear cells receptivity to sex steroid hormones in postmenopausal patients with endometrial proliferative processes

NCT ID: NCT06049693 Completed - Endometrial Cancer Clinical Trials

Iron Prehabilitation in Endometrial Cancer

IROGYN
Start date: January 1, 2023
Phase: Phase 4
Study type: Interventional

Endometrial cancer patients often have iron deficiency anemia before surgery, which can be effectively treated with oral iron supplementation. Anemia and blood transfusions have been previously associated with perioperative infectious diseases. In the present study the investigators will evaluate the impact of perioperative iron supplementation on the incidence of perioperative infections.

NCT ID: NCT05977829 Completed - Clinical trials for Endometrial Neoplasms

Endometrial Malignancy in Breast Cancer Patients With or Without AUB

TamAUB
Start date: January 1, 2020
Phase:
Study type: Observational

In order to assess the hysteroscopic, histopathologic, and ultrasonographic aspects of uterine monitoring in postmenopausal breast cancer patients with or without abnormal uterine bleeding (AUB), as well as to calculate the risk of endometrial cancer in women with or without AUB.

NCT ID: NCT05951426 Completed - Clinical trials for Endometrial Carcinoma Cellular Diagnosis

Expression Analysis of the COPB 2 and Bcl-2 in Early Stages of Endometrial Carcinoma

Start date: April 17, 2019
Phase:
Study type: Observational [Patient Registry]

COPB2 is a subunit of the intracellular transport system between cell organelles that participates in the regulation of cell division and differentiation. Bcl-2 is a protein that participates in regulating the process of apoptosis. Through the research,investigators tried to examine and establish the correlation of the expression of these two genes in endometrial cancer at an early stage.

NCT ID: NCT05914844 Completed - Clinical trials for Endometrial Cancer Stage

Investigation Of Receptivity Markers For Endometrial Cancer Treatment Development

Start date: November 19, 2021
Phase:
Study type: Observational

Hyaluronan is an extracellular matrix protein that is involved in cell-cell and cell-matrix interactions. Hyaluronan performs this activity through hyaladherins, which are intracellular and extracellular receptors. The purpose of this study was to compare the distributions of Hyaluronan Synthetase 2 (HAS2) and CD44s in healthy endometrial tissue samples obtained during the proliferative phase endometrium (PPE) and secretory phase endometrium (SPE), as well as pathologic samples diagnosed with benign endometrial hyperplasia (EH), endometrial intraepithelial neoplasia (EIN), early stage of endometrial carcinoma (EC) (stage I/II) and advanced stage of endometrial carcinoma (stage III/IV) (n:5, each). By using the avidin-biotin-peroxidase method, tissue samples that had been fixed with formalin passed through a regular paraffin follow-up protocol, and subsequently embedded in paraffin were stained indirectly with anti-CD44s and anti-HAS2 primary antibodies. Immunostaining intensity was graded as 0: negative, 1: weak, 2: moderate, 3: strong, and 4: very strong using a semiquantitative technique. The ANOVA test was used to assess the statistical significance of the findings. Statistical significance was defined as (p) values less than 0.05. While weak HAS2 and weak/moderate CD44s immunoreactivity was observed on the surface epithelium (SE)/glandular epithelium (GE) and stroma of the tissue samples acquired during PPE; weak/moderate HAS2 and moderate CD44s immunoreactivity were observed in SPE and EH groups; moderate/strong HAS2, strong CD44s immunoreactivity was observed in EIN; strong/very strong HAS2 and very strong CD44s immunoreactivity were observed in early-stage EC and advanced stage EC. It was determined that the immunoreactivity intensity increased at a statistically significant level in both early and advanced stage EC. The fact that HAS2 and CD44s, two intracellular receptors, have increased in endometrial carcinoma leads us to believe that they are likely to play a role in tumor development, invasion, migration, metastasis and that they may be useful in developing future treatment protocols targeting hyaluronan receptors.

NCT ID: NCT05542940 Completed - Endometrial Cancer Clinical Trials

P53 Immunohistochemistry Abnormal Staining in Endometrial Cancer

Start date: January 1, 2020
Phase:
Study type: Observational

Objective: Calculate the incidence of P53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types and grading. Patients and methods: 100 cases of endometrial cancer will be included in the study, recruited from Alexandria university hospital gyne-oncology unit. Surgical staging, histopathological examination and immunohistochemistry of p53 were done to all cases to calculate the incidence of P53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types, grading. Keywords: P53 immunohistochemistry, endometrial cancer, clinicopathological relation.